Drug Trial Radar · NCT05985655
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
230
Planned (sponsor's estimate)
Start
Jul 6, 2023
Primary completion
Jan 2028
Study completion May 2028
Sponsor
- Lead sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.
Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Pancreatic Adenocarcinoma
- Non-small Cell Lung Cancer (NSCLC)
- Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
- Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma
- Triple Negative Breast Cancer (TNBC)
Interventions
GTAEXS617Drug
Administered as specified in the treatment arm.
SoCDrug
Participants will receive selected SoC regimen (fulvestrant, paclitaxel + bevacizumab, pegylated liposomal doxorubicin, or capecitabine) administered as specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 2 years
- Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Up to 28 days
- Phase 2 : Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1Time frame: Up to 2 years
Locations
15 sites in 3 countries. Site status is shown where the registry gives one.
USC Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
START Midwest
Grand Rapids, Michigan · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
The Ohio State University
Columbus, Ohio · Recruiting
START San Antonio
San Antonio, Texas · Recruiting
START Mountain Region
West Valley City, Utah · Recruiting
GZA Ziekenhuizen - Campus Sint-Augustinus
Antwerp, Belgium · Recruiting
Clinique Universitaires Saint-Luc
Brussels, Belgium · Recruiting
Institute Jules Bordet
Brussels, Belgium · Recruiting
CHU Sart Tilman
Liège, Belgium · Recruiting
The Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom · Recruiting
UCL Hospitals NHS Foundation Trust
London, United Kingdom · Recruiting
The Christie NHS Foundation Trust
Manchester, United Kingdom · Recruiting
Newcastle Upon Tyne NHS Foundation Trust
Newcastle upon Tyne, United Kingdom · Recruiting
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.